These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 10969920

  • 21. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience.
    Mul D, Oostdijk W, Otten BJ, Rouwé C, Jansen M, Delemarre-van de Waal HA, Waelkens JJ, Drop SL.
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():765-72. PubMed ID: 10969919
    [Abstract] [Full Text] [Related]

  • 22. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B, Schulz U, Kluge M, Wandl-Vergesslich K, Waldhauser F.
    Wien Klin Wochenschr; 1995 Jul; 107(14):413-7. PubMed ID: 7668000
    [Abstract] [Full Text] [Related]

  • 23. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
    Antoniazzi F, Cisternino M, Nizzoli G, Bozzola M, Corrias A, De Luca F, De Sanctis C, Rigon F, Zamboni G, Bernasconi S.
    Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
    [Abstract] [Full Text] [Related]

  • 24. [Effect of treatment with gonadotropin releasing hormone analogues in girls with idiopathic central precocious puberty].
    Ságodi L, Sólyom E, Lombay B, Almási A, Vámosi I.
    Orv Hetil; 2012 Mar 18; 153(11):418-24. PubMed ID: 22390866
    [Abstract] [Full Text] [Related]

  • 25. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB.
    J Clin Endocrinol Metab; 1999 Jan 18; 84(1):44-9. PubMed ID: 9920060
    [Abstract] [Full Text] [Related]

  • 26. Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
    Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Mengarda F, Pietrobelli A, Tatò L.
    J Clin Endocrinol Metab; 2003 Mar 18; 88(3):1096-101. PubMed ID: 12629090
    [Abstract] [Full Text] [Related]

  • 27. MANAGEMENT OF ENDOCRINE DISEASE: Long-term outcomes of the treatment of central precocious puberty.
    Guaraldi F, Beccuti G, Gori D, Ghizzoni L.
    Eur J Endocrinol; 2016 Mar 18; 174(3):R79-87. PubMed ID: 26466612
    [Abstract] [Full Text] [Related]

  • 28. Predictive factors for the effect of gonadotrophin releasing hormone analogue therapy on the height of girls with idiopathic central precocious puberty.
    Brauner R, Malandry F, Rappaport R.
    Eur J Pediatr; 1992 Oct 18; 151(10):728-30. PubMed ID: 1425790
    [Abstract] [Full Text] [Related]

  • 29. [Treatment of central precocious puberty with Gonadotropin-Releasing Hormone agonist (triptorelin) in girls: breast development, skeletal maturation, height and weight evolution during and after treatment].
    Messaaoui A, Massa G, Tenoutasse S, Heinrichs C.
    Rev Med Brux; 2005 Feb 18; 26(1):27-32. PubMed ID: 15816337
    [Abstract] [Full Text] [Related]

  • 30. Prevention of bone demineralization by calcium supplementation in precocious puberty during gonadotropin-releasing hormone agonist treatment.
    Antoniazzi F, Bertoldo F, Lauriola S, Sirpresi S, Gasperi E, Zamboni G, Tatò L.
    J Clin Endocrinol Metab; 1999 Jun 18; 84(6):1992-6. PubMed ID: 10372699
    [Abstract] [Full Text] [Related]

  • 31. Final adult height in children with central precocious puberty - a retrospective study.
    Knific T, Lazarevič M, Žibert J, Obolnar N, Aleksovska N, Šuput Omladič J, Battelino T, Avbelj Stefanija M.
    Front Endocrinol (Lausanne); 2022 Jun 18; 13():1008474. PubMed ID: 36531464
    [Abstract] [Full Text] [Related]

  • 32. [Improvement of expected and final height in girls with central precocious puberty treated with gonadotropin releasing hormone analogues].
    Gómez F, Picó AM, Vargas F, Mauri M.
    Med Clin (Barc); 1996 Nov 23; 107(18):681-4. PubMed ID: 9082075
    [Abstract] [Full Text] [Related]

  • 33. Quantitative calcaneal ultrasound parameters and bone mineral density at final height in girls treated with depot gonadotrophin-releasing hormone agonist for central precocious puberty or idiopathic short stature.
    Kapteijns-van Kordelaar S, Noordam K, Otten B, van den Bergh J.
    Eur J Pediatr; 2003 Nov 23; 162(11):776-80. PubMed ID: 13680381
    [Abstract] [Full Text] [Related]

  • 34. Idiopathic precocious puberty versus puberty in adopted children; auxological response to gonadotrophin-releasing hormone agonist treatment and final height.
    Kempers MJ, Otten BJ.
    Eur J Endocrinol; 2002 Nov 23; 147(5):609-16. PubMed ID: 12444892
    [Abstract] [Full Text] [Related]

  • 35. The Influence of GnRH Analog Therapy on Growth in Central Precocious Puberty.
    Głąb E, Wikiera B, Bieniasz J, Barg E.
    Adv Clin Exp Med; 2016 Nov 23; 25(1):27-32. PubMed ID: 26935495
    [Abstract] [Full Text] [Related]

  • 36. GH and GnRH analog treatment in children who enter puberty at short stature.
    Tanaka T, Satoh M, Yasunaga T, Horikawa R, Tanae A, Hibi I.
    J Pediatr Endocrinol Metab; 1997 Nov 23; 10(6):623-8. PubMed ID: 9467133
    [Abstract] [Full Text] [Related]

  • 37. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A, Scheike T, Nielsen CT, Krabbe S, Müller J, Skakkebaek NE.
    J Clin Endocrinol Metab; 1995 Oct 23; 80(10):3059-67. PubMed ID: 7559897
    [Abstract] [Full Text] [Related]

  • 38. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF, Crawford JD, Crowley WF.
    Endocr Rev; 1986 Feb 23; 7(1):24-33. PubMed ID: 2937629
    [Abstract] [Full Text] [Related]

  • 39. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study.
    Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, Papaefstathiou A, Lalioti N, Kanaka-Gantenbein C, Piaditis G, Chrousos GP, Dacou-Voutetakis C.
    J Clin Endocrinol Metab; 2010 Jan 23; 95(1):109-17. PubMed ID: 19897682
    [Abstract] [Full Text] [Related]

  • 40. Combined treatment with gonadotropin-releasing hormone analog and growth hormone in central precocious puberty.
    Pasquino AM, Municchi G, Pucarelli I, Segni M, Mancini MA, Troiani S.
    J Clin Endocrinol Metab; 1996 Mar 23; 81(3):948-51. PubMed ID: 8772556
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.